

## **Establishing a Pharmacist-led CMV Stewardship Program to Reduce Hospital Admissions, Length of Stay, and CMV Resistance**

### **Resources**

1. Jorgenson MR, Descourouez JL, Kleiboeker H, et al. Cytomegalovirus antiviral stewardship in solid organ transplant recipients: A new gold standard. *Transpl Infect Dis*. 2022;24(5):e13864. doi:10.1111/tid.13864
2. Hensler D, Richardson CL, Brown J, et al. Impact of electronic health record-based, pharmacist-driven valganciclovir dose optimization in solid organ transplant recipients. *Transpl Infect Dis*. 2018;20(2):e12849. doi:10.1111/tid.12849
3. Wang N, Athans V, Neuner E, Bollinger J, Spinner M, Brizendine K. A pharmacist-driven antimicrobial stewardship intervention targeting cytomegalovirus viremia in ambulatory solid organ transplant recipients. *Transpl Infect Dis*. 2018;20(6):e12991. doi:10.1111/tid.12991
4. Patel T, Imlay H, Kaul D, Stuckey L, Gregg K. Ganciclovir-resistant CMV (GCV-R CMV) Infection Leads to Poor Clinical Outcomes and Economic Burden of Ganciclovir-resistant *Cytomegalovirus* Infection in Lung Transplant Recipients. *Open Forum Infect Dis*. 2017;4(Suppl 1):S730. Published 2017 Oct 4. doi:10.1093/ofid/ofx163.1967